Lovastatin

Peripheral Arterial Disease, Primary Hypercholesterolemia, Coronary Revascularization + 16 more
Treatment
20 Active Studies for Lovastatin

What is Lovastatin

LovastatinThe Generic name of this drug
Treatment SummaryLovastatin is a medication used to lower cholesterol levels and reduce the risk of cardiovascular disease. It is part of a class of drugs called statins, which work by blocking the enzyme that produces cholesterol in your liver. Lovastatin is generally well-tolerated, making it a popular choice for both adults and children. It is often prescribed after a cardiovascular event or for people with a moderate to high risk of developing CVD. Other medications in the statin class include atorvastatin, pravastatin, rosuvastatin, fluvastatin, and simvastatin. Studies have shown that
Mevacoris the brand name
image of different drug pills on a surface
Lovastatin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Mevacor
Lovastatin
1987
285

Effectiveness

How Lovastatin Affects PatientsLovastatin is a medication used to lower cholesterol levels. It reduces the amount of low-density lipoprotein (LDL) in the blood and increases levels of high-density lipoprotein (HDL), which can reduce the risk of developing cardiovascular disease. Clinical studies have found that taking lovastatin can reduce total cholesterol and LDL by 25-40%. However, taking lovastatin can also lead to muscle pain, tenderness or weakness, and in rare cases, even death. Taking lovastatin with other drugs such as fenofibrate, niacin, gemfibrozil, or cycl
How Lovastatin works in the bodyLovastatin works by blocking an enzyme that is important for producing cholesterol in the liver. This reduces the amount of cholesterol in the body and helps lower the risk of cardiovascular disease. It also has other effects on the body, including improving blood vessel function, stabilizing plaque in arteries, and reducing inflammation and oxidative stress. Lovastatin has also been linked to cancer prevention and treatment, by triggering cell death in certain cancer cells and increasing the expression of certain proteins that can help stop cancer growth.

When to interrupt dosage

The proposed portion of Lovastatin is reliant upon the determined condition, including Dyslipidemias, 1 year post-menarche and Cardiovascular Diseases. The extent of dosage fluctuates, based on the technique of delivery indicated in the table below.
Condition
Dosage
Administration
Heart Attack
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Cholesterol, LDL
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Diet
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Coronary Heart Disease
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Apolipoprotein
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Hypercholesterolemia
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Dyslipidemias
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Low-Density Lipoproteins
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Cardiovascular Diseases
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Hypertriglyceridemia
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
1 year post-menarche
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Coronary heart disease
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Angina, Unstable
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Coronary Artery Disease
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Low-Density Lipoproteins
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
total cholesterol increased
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Peripheral Arterial Disease
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Primary Hypercholesterolemia
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral
Coronary Revascularization
20.0 mg, 40.0 mg, , 10.0 mg, 60.0 mg
Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral

Warnings

Lovastatin has seven contraindications. For any of the conditions outlined in the following table, Lovastatin should not be consumed.Lovastatin Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Lovastatin may interact with Pulse Frequency
Liver Diseases
Do Not Combine
Breast Milk Production
Do Not Combine
Transaminases
Do Not Combine
Pulse Frequency
Do Not Combine
unexplained elevations of serum transaminases
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Lovastatin.
Common Lovastatin Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Lovastatin.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Lovastatin.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Lovastatin.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Lovastatin.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Lovastatin.
Lovastatin Toxicity & Overdose RiskThe lethal dose of lovastatin is higher than 15 g/m2. Five people took up to 200 mg of the drug without any major side effects. Although some people have taken accidental overdoses of lovastatin, none of them experienced any symptoms and recovered without any long-term effects. Studies have indicated that lovastatin may increase the risk of liver cancer, lung tumors, stomach and thyroid tumors, and may cause testicular atrophy, reduced sperm production, and decreased fertility in males. There is no evidence that lovastatin is mutagenic.
image of a doctor in a lab doing drug, clinical research

Lovastatin Novel Uses: Which Conditions Have a Clinical Trial Featuring Lovastatin?

134 active trials are currently underway to assess the potency of Lovastatin in Coronary Artery Atherosclerosis, Heart Attack and Coronary Heart Disease management.
Condition
Clinical Trials
Trial Phases
Peripheral Arterial Disease
36 Actively Recruiting
Not Applicable, Phase 3, Phase 1, Early Phase 1, Phase 2, Phase 4
Apolipoprotein
0 Actively Recruiting
Hypercholesterolemia
4 Actively Recruiting
Phase 1, Phase 3
Hypertriglyceridemia
0 Actively Recruiting
Coronary Artery Disease
1 Actively Recruiting
Not Applicable
Angina, Unstable
2 Actively Recruiting
Not Applicable
Coronary Revascularization
1 Actively Recruiting
Phase 4
Coronary Heart Disease
6 Actively Recruiting
Not Applicable, Early Phase 1
Cholesterol, LDL
0 Actively Recruiting
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Low-Density Lipoproteins
0 Actively Recruiting
Heart Attack
23 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Early Phase 1, Phase 3
Coronary heart disease
0 Actively Recruiting
Primary Hypercholesterolemia
8 Actively Recruiting
Phase 3, Phase 2, Not Applicable
Dyslipidemias
1 Actively Recruiting
Phase 2
1 year post-menarche
0 Actively Recruiting
total cholesterol increased
0 Actively Recruiting
Low-Density Lipoproteins
0 Actively Recruiting
Cardiovascular Diseases
0 Actively Recruiting

Lovastatin Reviews: What are patients saying about Lovastatin?

5Patient Review
10/26/2018
Lovastatin for Changes Involving Fatty Deposits in the Blood Vessels
I've been taking this for a while now and it's really helped me. However, I recently developed scleroderma, which my doctor thinks might be caused by this medication. If anyone else has had a similar experience, please let me know.
5Patient Review
10/16/2020
Lovastatin for High Cholesterol
I don't think I'll be renewing my prescription for this pill. It doesn't agree with my stomach since they switched manufacturers, and I'm currently taking the generic teva 576 version.
4.3Patient Review
5/1/2014
Lovastatin for High Cholesterol
3.7Patient Review
9/28/2017
Lovastatin for High Cholesterol
After taking Lovastatin for a few months, I realized that the drug was causing me a lot of pain. I now wonder how long it will take to get out of my system. The side effects are really bad and this drug should be banned.
3.7Patient Review
8/8/2014
Lovastatin for Combined High Blood Cholesterol and Triglyceride Level
I experienced more frequent bowel movements and swelling in my lower extremities while taking this medication.
3.3Patient Review
12/16/2015
Lovastatin for High Cholesterol
I was warned about potential muscle pain before starting this medication, and unfortunately I experienced exactly that within just ten days. The weakness and pain was so severe that I had to stop taking the medication and my doctor took me off of it. It's been two months now and I'm still struggling with the aftermath.
3.3Patient Review
11/10/2017
Lovastatin for High Cholesterol
Though this drug worked as it was supposed to, the side effects were not worth it for me. These included gas, loose bowel movements, sporadic muscle and bone pain, and pains in the back of my eyes. All of these effects were erratic and unpredictable.
3Patient Review
8/2/2015
Lovastatin for High Cholesterol
I experienced some pretty severe pain while taking this drug, to the point where I could hardly move. It's been a few weeks and I'm still feeling the effects. Overall, not a great experience.
3Patient Review
9/7/2014
Lovastatin for High Cholesterol
After the pharmacy switched to a different manufacturer for my Lovastatin, I started breaking out in hives. It took weeks for me to connect the dots, but as soon as I stopped taking the medication, the hives cleared up. Not sure if it was an ingredient in the new pills or the Lovastatin itself that caused the reaction.
3Patient Review
7/25/2014
Lovastatin for Combined High Blood Cholesterol and Triglyceride Level
3Patient Review
2/3/2015
Lovastatin for High Cholesterol
I am not a fan of this treatment. I have most of the listed side effects, and my doctor says it's just because of my age. I don't think that's true though; Lovastatin has really put a damper on my quality of life.
2.7Patient Review
4/3/2014
Lovastatin for High Cholesterol
2.3Patient Review
9/22/2014
Lovastatin for High Cholesterol
I have had one knee replacement and one corrective knee surgery, Laminectomy L-1 thru L-5 and now have arthritis in the right hip. Never had any problems prior to taking STATIN drugs but I due have great LDL test results.
2.3Patient Review
2/9/2019
Lovastatin for High Cholesterol
I've been taking this drug for a decade now, three times 20 mg per day. I have experienced some muscle problems, but nothing major.
2Patient Review
11/1/2015
Lovastatin for High Cholesterol
I've been on this statin for a while, but in the past few years I've started to experience sore, inflamed joints. My hair has also been falling out more, but my doctor said that's just due to stress. I'm hoping to switch to something else soon as this isn't working well for me.
1.7Patient Review
5/18/2018
Lovastatin for High Cholesterol
I've been on Lovastatin for a while now, but about eight months ago I started having weird tingling and burning sensations at the bottom of my feet. I've seen two different foot doctors and had all sorts of tests done (MRI's, nerve conduction, etc.), but they still can't figure out what's wrong. I'm starting to wonder if it might be the Lovastatin.
1Patient Review
12/26/2016
Lovastatin for High Cholesterol
I started taking lovastatin a few weeks ago and unfortunately had to stop because the stomach pains, backaches, and general aches in my limbs were too much. I'm hoping these side effects will dissipate soon.
1Patient Review
11/11/2014
Lovastatin for High Cholesterol
I'm not sure if this treatment also lowers blood pressure, as I have not experienced that side effect. Has anybody else?
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about lovastatin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What's the difference between statin and lovastatin?

"There are two types of statins, simvastatin and lovastatin. Simvastatin is more effective at lowering cholesterol levels, while lovastatin is reserved for drug combinations or if a patient has an undesirable reaction to simvastatin."

Answered by AI

Is lovastatin a blood thinner?

"Statin medications not only improve the cardiovascular system by working on the inner lining of blood vessels and the heart muscle, but they also have a side effect of decreasing the blood's clotting ability. This is generally seen as a beneficial side effect with no increased risk of internal bleeding."

Answered by AI

What is the difference between Crestor and lovastatin?

"Crestor is one of the most effective statins to improve cholesterol and is also available as a generic. It lowers cholesterol. Mevacor can improve cholesterol, but it is not as strong as other statin medicines."

Answered by AI

What is the side effect of lovastatin?

"Lovastatin can cause an allergic reaction that makes it hard to breathe or swallow. Other symptoms include swelling in your face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs."

Answered by AI

Clinical Trials for Lovastatin

Image of University of Nebraska at Omaha Health Science Collaborative in Omaha, United States.

Pulse Arrival Time for Peripheral Artery Disease

18+
All Sexes
Omaha, NE
1\) The purpose of this study is to assess segmental pulse arrival time (PAT) as an alternative biomarker to detect lower-extremity peripheral artery disease (PAD). The secondary purpose will be to investigate the impacts of age on segmental PAT. The subject population will include any adults 19 years of age or older with or without PAD. Exclusion criteria include having an aortic aneurysm with or without previous intervention, previous revascularization surgeries of the arteries in the legs/aorta, walking impairments independent of PAD, gangrene or ulcers of the toes/feet, and currently pregnant or breastfeeding. 3) All aims of the present study will be completed with a single laboratory visit. Descriptive measurements will include height, weight, age, sex, body fat percentage, and self-reported medication and health history. Subjects will lie in the supine position for 20-min. After rest, either the ankle-brachial index (ABI) or PAT will be assessed. After 10-min of further rest, the other measurement will be performed. ABIs will be assessed according to current guidelines: blood pressures will be assessed in the dorsal pedis and tibialis posterior arteries of both legs and the brachial arteries of both arms using a blood pressure cuff and Doppler ultrasound. PAT will be simultaneously assessed in both arms and legs using an investigational device with a 3-lead electrocardiogram sensor and four photoplethysmography (PPG) sensors. A PPG sensor will be applied to both middle fingers and both big toes. Signals will be collected for 15-min. Thermal images of the fingers and toes will be assessed before and after using the investigational device. After assessment of ABI and PAT, subjects will participate in a 6-min walking test (6MWT) to objectively establish walking capacity. The 6MWT will be performed in accordance with current guidelines. Cones will be separated by 30 meters on a straight flat walkway. Subjects will be instructed to walk back and forth between the cones as fast as they can for 6-min. Subjects will be allowed to rest during the test, if necessary, but the stopwatch will continue to run. Segmental PATs will be compared with ABI and 6-min walking time to determine if segmental PATs can predict lower-extremity PAD (ABI) and the associated walking impairment (6MWT). This study is expected to last \~2hrs. 4) There will be no follow-up.
Waitlist Available
Has No Placebo
University of Nebraska at Omaha Health Science Collaborative
Image of St Boniface Hospital in Winnipeg, Canada.

Remote Home Monitoring for Heart Attack

18+
All Sexes
Winnipeg, Canada
Heart attacks are one of the top causes of death in Canada, with over 2,100 cases treated each year in Manitoba. Even though hospital care has improved, the period after going home is still risky. Many patients feel anxious and unsure about their recovery, and without enough support, they often end up back in the emergency department (ED). This is an even bigger challenge for people in rural areas, where getting follow-up care can be much harder. Filling these gaps is important to help patients get better and to reduce stress on the healthcare system. In a previous study, the investigators found that extra support made a big difference: only 8% of participants using a digital health tool returned to the ED within 30 days, compared to 22% of participants without it. Now, the investigators want to expand this study across Manitoba to see if digital health tools can help more people recover safely at home. The investigators will compare two types of follow-up care: education only versus education with extra support (like symptom tracking and virtual appointments). The investigators will look at how this affects hospital visits, mental well-being, and healthcare costs. The goal is to create a better support system for people after a heart attack, leading to healthier recoveries, less strain on hospitals, and better care for Manitobans - no matter where they live.
Waitlist Available
Has No Placebo
St Boniface Hospital
Have you considered Lovastatin clinical trials? We made a collection of clinical trials featuring Lovastatin, we think they might fit your search criteria.Go to Trials
Image of Metabolic & Atherosclerosis Research Center in Cincinnati, United States.

Lerodalcibep for High Cholesterol

6 - 17
All Sexes
Cincinnati, OH
The goal of this clinical trial is to assess the LDL-Cholesterol reductions at Week 12 and Week 24 with monthly dosing of lerodalcibep (Lerochol) 300 mg administered subcutaneously by auto-injector (AI)/pre-filled pen (PFP) compared to placebo (dummy), in male and female pediatric patients 6 to 17 years of age, with inherited high cholesterol (HeFH) on a stable diet and maximally tolerated oral LDL C lowering drug therapy such as statins. The main question\[s\] it aims to answer are: How effective is Lerochol in reducing LDL cholesterol? How well is it tolerated and are there any safety concerns? Researchers will compare Lerochol to placebo (inert or dummy injection solution). Participants will visit the clinic every month for months and be asked to fast overnight, but allowed to drink water, before clinic visits. Undergo physical exams, height and weight measurements, answer questions, have blood drawn from a vein in their arm, have blood pressure measurements, EKC heart tests, and receive monthly injections lasting about 5 seconds in their arms or abdomen with an autoinjector.
Phase 3
Waitlist Available
Metabolic & Atherosclerosis Research CenterDavid Kallend, MB BSLIB Therapeutics LLC
Image of Research Site in Chula Vista, United States.

AZD0780 for Hypercholesterolemia

18+
All Sexes
Chula Vista, CA
This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.
Phase 3
Recruiting
Research Site (+28 Sites)AstraZeneca
Image of Tampa General Hospital in Tampa, United States.

Fasting for Myocardial Infarction

18+
All Sexes
Tampa, FL
The goal of this clinical trial is to find out whether fasting is necessary before urgent inpatient cardiac catheterizations. For patients presenting with urgent heart-related pain or even mild heart attacks, researchers want to know whether eating and drinking before their procedure improves comfort without raising the risk of complications. The study will answer: * Does eating and drinking before the procedure improve patient comfort? * Does it increase the risk of adverse events like vomiting, aspiration (food or liquid entering the lungs), breathing problems, or death, etc? Participants will be randomly assigned to either: * A standard fasting group (no food for 6 hours, no clear liquids for 2 hours), or * A no-fasting group (able to eat and drink as usual). Patients will complete brief surveys before the procedure to assess comfort and satisfaction. Researchers will also review medical records weekly and 30 days later to monitor for safety outcomes.
Recruiting
Has No Placebo
Tampa General HospitalSamip Vasaiwala, MD
Image of Abcentra Investigational Site in Los Angeles, United States.

Orticumab for Heart Attack

18+
All Sexes
Los Angeles, CA
The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies
Phase 2
Recruiting
Abcentra Investigational Site (+6 Sites)Abcentra
Have you considered Lovastatin clinical trials? We made a collection of clinical trials featuring Lovastatin, we think they might fit your search criteria.Go to Trials
Have you considered Lovastatin clinical trials? We made a collection of clinical trials featuring Lovastatin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security